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Generation of potent antibodies by a mutation-
selection process called affinity maturation is a key
component of effective immune responses. Anti-
bodies that protect against highly mutable patho-
gens must neutralize diverse strains. Developing
effective immunization strategies to drive their evolu-
tion requires understanding how affinity maturation
happens in an environment where variants of the
same antigen are present. We present an in silico
model of affinity maturation driven by antigen vari-
ants which reveals that induction of cross-reactive
antibodies often occurs with low probability because
conflicting selection forces, imposed by different an-
tigen variants, can frustrate affinity maturation. We
describe how variables such as temporal pattern of
antigen administration influence the outcome of
this frustrated evolutionary process. Our calculations
predict, and experiments in mice with variant gp120
constructs of the HIV envelope protein confirm, that
sequential immunization with antigen variants is
preferred over a cocktail for induction of cross-reac-
tive antibodies focused on the shared CD4 binding
site epitope.INTRODUCTION
Antibodies (Abs) with high affinity for antigen are produced by the
process of affinitymaturation (AM), which takes place in germinal
centers (GCs). GCs are dynamic structures within secondary
lymphoid tissues that arise in response to antigen stimulation
(Shlomchik and Weisel, 2012; Victora and Nussenzweig, 2012).GCs house B cells, antigen-specific T helper cells that develop
in concert with GC B cells (Baumjohann et al., 2013; Kelsoe,
1996) and antigens presented on follicular dendritic cells
(FDCs) (Figure 1A). GC B cells enhance the antigen affinity of
their receptors by 10- to 1,000-fold through cycles of mutation
and selection against antigens presented on FDCs, a Darwinian
evolutionary process that occurs on a very short timescale. Sol-
uble forms of the high-affinity receptors are potent Abs. AM has
been studied extensively using diverse experimental methods
(Batista and Neuberger, 1998; Berek and Milstein, 1987; Berek
et al., 1991; Eisen and Siskind, 1964; Jacob et al., 1991; Kocks
and Rajewsky, 1988), mathematical models (Deem and Lee,
2003; Kepler and Perelson, 1993; Meyer-Hermann, 2002,
Meyer-Hermann et al., 2006; Oprea and Perelson, 1997; Zhang
and Shakhnovich, 2010), and computer simulations (Kesxmir
and De Boer, 2003; Shlomchik et al., 1998; Swerdlin et al.,
2008). Recent experiments have uncovered new aspects of
GC dynamics (Allen et al., 2007; Shulman et al., 2013; Victora
et al., 2010).
Effective Ab responses are likely to be required for a protective
prophylactic vaccine against highly mutable pathogens. For HIV,
a quintessential example of such a pathogen, there has been no
definitive success in designing such a vaccine, despite extensive
efforts (Burton et al., 2012; Klein et al., 2013; Kwong et al., 2013;
Mascola and Haynes, 2013). This is in large part due to the vari-
ability of HIV (Burton et al., 2012; Mascola and Haynes, 2013).
The protective effects of an Ab are predicated on its ability to
bind to a set of residues (the epitope) on the surface of virions.
For example, the HIV-1 envelope glycoprotein trimer (Env) is
the sole target of known HIV-1 neutralizing Abs (Burton et al.,
2012; Kwong et al., 2013; Mascola and Haynes, 2013; West
et al., 2014). During the first few months of infection, the induced
neutralizing Abs are primarily strain-specific and target variable
regions of Env. As the concentrations of such strain specific
Abs increase, neutralization escape variants with mutations
in the variable epitopes are selected. A pathogen’s molecularCell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc. 785
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Figure 1. Schematic Depiction of In Silico Model
(A) Players and processes in the GCR.
(B) Major steps in our in silico model of the GCR.
(C) Model for BCR-Ag interactions. Left: A BCR interacting with an FDC-held Ag. Right: A zoom-in view of interactions (bars) between the residues on the BCR
paratope and those on the Ag epitope. An affinity-affecting mutation on a paratope residue will change its interaction strength h with the corresponding epitope
residue, denoted by hc (hv) if the latter is conserved (variable).
(D) Conformational coupling between residues on the BCR is incorporated via correlated changes in hc and hv; weakening interaction with the variable residues
and the residues that shield the conserved residues of the epitope (red symbols), i.e., hvY, would facilitate access to the conserved residues (green symbols),
i.e., hc[.
See also Figure S1.surfaces that interact with host receptors (e.g., the CD4 binding
site) provide epitopes that contain a relatively conserved set of
residues. They can serve as targets for Abs that are able to
neutralize a greater diversity of HIV strains. A shield of glycans
and immunodominant variable loops can restrict antibody ac-
cess to these relatively conserved epitopes (Julien et al., 2013;
Kwong et al., 2002; Lyumkis et al., 2013; Pancera et al., 2014;
Wei et al., 2003; Wyatt et al., 1998). Yet, some HIV-1 infected in-
dividuals do develop Abs that focus on such epitopes and
neutralize a broad cross section of HIV strains in vitro (Kwong
et al., 2013). However, these broadly neutralizing antibodies
(bnAbs) are produced only beginning around 2 years after infec-
tion and in only a limited fraction of chronically infected patients.
Nonetheless, the emergence of bnAbs in some patients is proof
that AM can result in bnAbs. This suggests the tantalizing possi-
bility that appropriately designed immunogens and immuniza-
tion protocols may be able to elicit bnAbs rapidly in a large frac-
tion of individuals, thus resulting in an effective vaccine.
Recent longitudinal tracking of a developing HIV-1 bnAb line-
age and the co-evolving virus in a patient showed that extensive,786 Cell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc.and even specifically directed, viral diversification occurred prior
to the development of breadth (cross-reactive Abs) (Gao et al.,
2014; Liao et al., 2013), supporting the idea that escape mutants
of the virus drive bnAb evolution. More importantly, this observa-
tion highlights that induction of bnAbs will likely require immuni-
zation with multiple variants of the antigen.
When multiple complex antigen variants are used as immuno-
gens, several new questions become important, for example: (1)
which antigen variants should be used as immunogens; (2) what
should be the concentrations and temporal order in which they
are administered (e.g., cocktails versus sequential)? The an-
swers to these questions are drawn from a huge number of
possibilities, and random selection from a large number of com-
binations of optionsmay not allow sufficient sampling to find effi-
cacious strategies. Intuition is unlikely to guide choices correctly
because a mechanistic understanding of how AM occurs in the
face of variant or mutating antigens is not available, as past
studies have focused on AM in response to single model anti-
gens. This gap in basic immunobiology needs to be addressed.
A fundamental understanding of AM induced by several antigen
variants that mimic the complexity of how conserved epitopes
are shielded on the intact viral spike could be harnessed to
design optimal immunogens and immunization protocols for
the development of universal vaccines against highly mutable
pathogens (e.g., HIV-1, influenza).
To take steps toward these goals, we developed an in silico
model of AM induced by variant antigens. This stochastic dy-
namic model enables examination of the key mechanisms and
factors that influence AM in the face of variant antigens and
the development of bnAbs. Our calculations predict markedly
distinct outcomes if designed antigen (Ag) variants are presented
in different concentrations and temporal patterns during im-
munization. Experiments in mice using model HIV antigens are
consistent with these predictions. Thus, our complementary
computational and experimental results provide broadly appli-
cable fundamental insights, and a guide for further studies aimed
at overcoming roadblocks to the induction of bnAbs against HIV-
1 by vaccination.
RESULTS
In Silico Model
The purpose of our in silico modeling is not quantitative recapitu-
lation of existing experiments but to provide fundamental mech-
anistic insights into AM induced by multiple Ag variants and to
compare the predicted relative efficacy of different immunization
schemes in inducing cross-reactive broadly neutralizing Abs
(bnAbs). Two key features not considered before must be incor-
poratedexplicitly in such studies; viz., thepresenceofmultipleAg
variants during GC reactions and the molecular complexity of
the Ags. To mimic interactions of B cell receptors with complex
immunogens such as the HIV-1 trimeric spike, we account for
the fact that the conserved protein epitope of desired Abs are
partially shielded, and that insertions and deletions in the variable
loops can hinder the formation of strong interactions with the
conserved residues of the epitopes (e.g., those in the CD4bs).
We computationally simulate the dynamics of a typical GC
(Figure 1A). The GC reaction (GCR) starts on day 3 (Nieuwenhuis
and Opstelten, 1984) after Ag injection, with three B cell blasts
(Jacob et al., 1991; Kroese et al., 1987) that barely meet a rela-
tively low-affinity threshold, Ea. The qualitative results we report
do not depend on the particular value of Ea since all other affin-
ities are scaled relative to it. The B cells expandwithoutmutation,
reaching a population size of about 1,500 cells around day 7
(Jacob et al., 1991).
Hypermutation in the Dark Zone of the GC
At day 7, AID-mediated somatic hypermutation (SHM) in the
immunogloblin (Ig) genes turns on (Ka¨llberg et al., 1996) with a
rate of 103 per base pair per division (Berek and Milstein,
1987). Variations in the time at which SHM begins do not affect
our results as we start timing AM processes after this point.
Each B cell in the dark zone of theGC (the region where this repli-
cation/mutation occurs) replicates twice, and we assume that
mutation occurs uniformly, neglecting preferential replacements
or hypermutation hotspots (Wagner et al., 1995).We assume that
the activated B cells are from an appropriate germline (Kepler
et al., 2014). The probability of a functionally silent mutation
(no change in affinity) is pS = 0.5, the probability that a mutationis lethal (e.g., non-folding) is pL = 0.3, and the rest are affinity-
affecting mutations (probability pA = 0.2) (Shlomchik et al.,
1998). For affinity-affecting mutations, the affinity of a BCR (i)
with a particular type of antigen (j), Eij, is changed. The extent
of the change is chosen from a probability distribution character-
ized by a long tail of deleterious mutations that reduce affinity, as
experimental data suggest that favorable mutations are less
likely than deleterious ones (Figure S1A). Our BCR-Ag affinity
model is defined in a later sub-section.
Selection in the Light Zone of the GC
B cells whose re-expressed surface Ig genes do not carry lethal
mutations then go through affinity-dependent selection. Two
survival signals are required for a B cell to be positively selected.
First, the BCR on a B cell must bind to the Ag (immunogen) dis-
played on the FDC sufficiently strongly to enable internalization.
Since processes occur stochastically, in our simulations, B cells
internalize Ag with a probability related to the binding affinity of
its BCR for the Ag. The greater the difference between the affinity
(Eij) of a B cell (i) for its epitope on Ag j and a threshold (Ea)
required for Ag internalization, the greater the probability of Ag
internalization. This probability is described mathematically in
analogy with a Langmuir isotherm (Equation 1 in Experimental
Procedures).
B cells that internalize Ag display antigenic peptides (p) bound
to major histocompatibility complex (MHC) molecules on their
surface. T cell receptors expressed on T helper cells can bind
to these pMHCs to deliver a key survival signal. B cells compete
with each other for the limited availability of T cell help (Victora
et al., 2010). T helper cells are specific for peptides derived
from the Ag, but they are responsive to diverse pMHCs, not
just those derived from the epitope targeted by the BCR. Thus,
we assume that the probability of a B cell receiving T cell help
is dictated by the amount of internalized Ag, regardless of the
identity of its targeted epitope. A B cell that successfully internal-
izes Ag receives T cell help with a probability that depends upon
its probability of internalizing Ag relative to the average probabil-
ity of internalizing Ag of all the other B cells present in the GC
(Equation 2 in Experimental Procedures). A B cell with a high af-
finity for its target epitope competes better for T cell help.
To study AM against Ag variants that may be present simulta-
neously, we have to confront an issue for which no experimental
information exists: when aGCB cell encounters a FDC, with how
many types of Ag variants can it simultaneously interact? We
consider two scenarios: (1) each GC B cell interacts with one
type of Ag variant during an encounter, or (2) each GC B cell in-
teracts simultaneously with all Ag variants held on the FDCs. We
find that which of these scenarios describes the heterogeneity of
Ag display on FDCs strongly influences the outcome of AM, indi-
cating the importance of experimental interrogation of this issue.
We study two extreme cases of competition for T cell help: (1)
GC B cells compete only with contemporary GC B cells (‘‘peers
only’’) and (2) in addition to current GC B cells, all antibodies
generated in previous rounds of mutation/selection also partici-
pate in the competition (‘‘Ab feedback’’). Reality should be
bounded by these scenarios.
Recycling, Differentiation, and Termination of the GCR
From seminal studies (Oprea and Perelson, 1997), 90% of
the selected cells are recirculated to the dark zone. The restCell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc. 787
differentiate into equal numbers of Ab-secreting plasma cells
and memory cells that can re-expand upon future activation.
Ab feedback is provided by objects in our agent-based model
with affinities representing these past GC emigrants. As AM pro-
ceeds, at first, the number of B cells in the GC decreases. In
some cases, all B cells apoptose and the GC extinguishes. In
others, upon reaching a population bottleneck, favorable clones
emerge, and the number of B cells rises (Zhang and Shakhno-
vich, 2010). We terminate the GCR once the GC population re-
covers to the initial size (i.e., 1,500 cells), or when an assumed
maximum duration of 120 days (or 240 GCR cycles) is reached,
whichever comes first. The first condition reflects the fact that an
abundance of GC B cells will internalize all the Ag on FDCs. The
second condition may reflect antigen decay over time which we
do not model explicitly.
Model for BCR-Ag Affinity
In classic computational studies focused onGCR stimulated by a
singlemodel Ag, B cells were binned into different affinity classes
for the Ag (e.g., Kepler and Perelson, 1993). The correlated affin-
ities for different Ag variants require a more detailed description.
Other studies have considered mathematical models (such as
NK-models) for BCR properties and their Ag affinity that present
rugged landscapes for affinity evolution (Deem and Lee, 2003).
To unambiguously define affinity to different Ag variants and to
consider complex immunogens that reflect features on viral
spikes, we developed a coarse-grained model with ‘‘residue-
level’’ resolution for key BCR-Ag interactions (Figure 1C). Our
modelwas inspiredby theCD4bson the trimericHIV-1 viral spike,
which is targeted by many monoclonal bnAbs for HIV-1 (Burton
et al., 2012). But, it applies to other epitopes that contain highly
conserved residues and can easily be modified to consider other
pathogens. We ignore distracting epitopes that do not contain
conserved residues because they are less likely to elicit bnAbs.
BCRs can potentially make contacts with three types of resi-
dues on the viral spike: (1) highly conserved residues of the
epitope (18 such residues in model); (2) residues representing
motifs, such as glycan attachment sites, which, when occupied,
can be associated with sterically blocking access to the
conserved residues (6 such residues in model); and (3) variable
residues, which upon mutation (includes insertions/deletions),
can further mask the conserved residues of the epitope. We
include 22 such residues from the variable loops of Env that
mimic the most mutable sites in the Seaman neutralization test
panel (Seaman et al., 2010; Walker et al., 2011) sequences and
publicly available Env sequences.
Each epitope residue is described in a coarse grainedmanner,
such that it is either the wild-type (WT) amino acid or a mutant.
The strength of interaction of a residue (k) on BCR (i) with a res-
idue on the epitope is denoted by hik . The binding affinity, Eij, be-
tween a B cell clone h
!i
and a viral strain s!j is modeled as
Eij

h
!i
; s!j

=
XM
k = 1
hik s
j
k +
XN
k =M+ 1
hik : (1)
The first M interactions (i.e., k% M) are with variable contact
residues on the viral spike, where sk can be either 1 (WT) or 1
(mutated). The other (NM) sites (i.e., k>M) are conserved resi-
dues on the epitope with sk = 1. The interaction strength hk is788 Cell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc.drawn from a continuous and uniform distribution within a
bounded range (details in ‘‘Simulation Methods’’ in Extended
Experimental Procedures).
Equation 1 is, however, just a starting point for the affinity be-
tween a particular BCR and Ag, as BCRs do not interact with
peptide chains in a linear fashion, and interactions between res-
idues are not independent, as Equation 1 may imply. Epitope-
paratope interactions are distinctly 3-dimensional, and structural
aspects of CD4bs bnAbs also point to the importance of how in-
teractions with some residues on the viral spike might influence
interactions with other epitope residues (Zhou et al., 2010). For
instance, most CD4bs bnAbs avoid contact with almost the
entire V1/V2 loop except for a few conserved residues near the
stem, and the very potent VRC01 Ab avoids the V5 loop. This
suggests that avoiding interactions with some residues can allow
better access and stronger interactions with the conserved res-
idues of the epitope. Furthermore, affinity enhancement of
bnAbs (such as VRC01) is influenced by alteration of non-contact
residues (Klein et al., 2013). We account for these effects as
described below (mathematical details in ‘‘Simulation Methods’’
in Extended Experimental Procedures).
BCR mutations that strengthen (weaken) interactions with the
residues that shield the conserved residues could result in a
decreased (increased) binding strength (value of h in Equation
1) for a randomly chosen paratope residue that can potentially
interact with a conserved residue on the epitope. This feature re-
flects the fact that BCRs that decrease contacts with shielding
residues are more likely to be able to access and make contacts
with the protected conserved residues.
Current knowledge on Env structures (Julien et al., 2013;
Lyumkis et al., 2013; Pancera et al., 2014) indicates that V1 is
likely to be a dynamic, unfolded, and disordered flexible loop,
and mutations in V2, especially insertions/deletions, can hide
the conserved residues of a neutralizing epitope. So, paratope
alterations that weaken interaction with a mutated variable
loop residue result in an increased binding strength (value of h
in Equation 1) for a randomly chosen paratope residue that can
potentially interact with a conserved residue on the epitope (Fig-
ure 1D), and vice versa.
Choice of Immunogens and Immunization Schemes
In silico, we study three Ag variants, the WT Ag (only unmutated
residues) and two mutants. Of the 22 most mutable residues in
the variable loops, 20 residues are mutated in the majority of
the 141 Seaman test panel sequences (Figure S1B). As these
highly mutated strains are viable, to maximize the number of
non-overlappingmutated residues on theAg variants,we studied
twomutant strains with 11 non-overlapping mutations in the var-
iable sites. We also studied variants with 4 and 8 suchmutations.
We assume that these Ag variants are not so distal in sequence
space that they stimulate completely different B cell lineages.
We investigate three immunization schemes in silico: (1)
scheme I (WT+v1+v2): WT Ag and two variants administered
as a cocktail. (2) scheme II (WTjv1+v2): Immunization with WT
Ag first, followed by administration of the two variants simulta-
neously. (3) scheme III (WTjv1jv2): Immunization withWTAg first,
followed by sequential administration of the two variants. In our
murine experiments we studied schemes I and III.
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Figure 2. Concentration Dependence of GC
Survival and Antibody Breadth in ‘‘WT First’’
Schemes
(A–C) For a relevant range of Ag concentrations
(Ctot), the fraction of surviving GCs (%surv, blue)
and their Ab breadth (red) are shown for (A)
scheme II (see 1 Ag), (B) scheme II (see both Ag)
and (C) scheme III, with full (left column) or none
(right column) Ab feedback. See also Figures S2
and S3.For each immunization protocol, we simulate many GC reac-
tions. When all steps of immunization and AM are completed,
we check whether the affinity of each Ab produced by a GC ex-
ceeds a threshold value against each strain in the Seaman panel.
Thus, we assess the breadth of cross-reactivity. The breadth of
coverage is defined as the fraction of test panel sequences to
which an Ab binds with an above-threshold affinity. We collect
statistics from many Abs and simulations, and report results
as histograms or probabilities of obtaining Abs with a certain
breadth. As many GCs are induced in each vaccinated person,
these results reflect the probability of obtaining Abs that exhibit
particular breadths of coverage in a typical individual.
Model Reproduces Known Features of Affinity
Maturation with a Single Antigen
Immunization with only the WT Ag leads to affinity enhancement
on conserved and variable residues alike (Figure S1E). The num-
ber of accumulatedmutations (seven affinity-affecting mutationsCell 160, 785–797,in 2 weeks, Figure S1D) and the incre-
mental changes in interaction strength
(Figure S1E) are consistent with experi-
ment (Berek et al., 1991; Kocks and Ra-
jewsky, 1988; Wedemayer et al., 1997).
Higher affinity clones continuously
emerge, producing potent Abs (Figure S2
C and F).
The Effect of Antigen
Concentration
For a single Ag, if Ag dose is too low (Fig-
ures S2A–S2B and S2D–S2E, lowest
Cwt), B cells are unlikely to be selected
during GC reactions, the GC collapses,
and there is no Ab production. If Ag
dose is too high (Figures S2A–S2B and
S2D–S2E, highest Cwt), selection is
easy, there is little competition between
B cells, and GCs are rapidly filled with
low-affinity clones (Eisen and Siskind,
1964; Goidl et al., 1968). Our agent-
based stochastic approach naturally
reproduces the inverse correlation be-
tween Ag concentration and heterogene-
ity in Ab affinities (Figures S2G and S2H)
observed in early experiments (Eisen and
Siskind, 1964).
For the three immunization schemes with antigen variants, Ag
concentration is again a very important variable (Figure 2). If the
Ag concentration is too low, most GCs collapse as expected.
However, there is a curious decline in GC survival and Ab
breadth if the Ag concentration is too high for immunization
schemes II and III. During AM after immunizing with a high
dose of WT Ag, many B cells survive easily and the GC reaction
draws to an end quickly. Therefore, these B cells are largely low-
affinity clones that have not accumulated mutations that
enhance contacts with the conserved residues of the epitope.
So, upon administering either a cocktail of the two Ag variants
or just one variant, these B cells have a small chance of binding
sufficiently strongly with the mutants and surviving, and so GCs
collapse despite the abundance of Ag. The few Abs produced do
not develop breadth as the large number ofmutations required to
confer breadth do not evolve (see examples in Figure S3).
Hereon, for each immunization scheme, we show results for
the Ag concentration (listed in Table 1) that yields Abs with aFebruary 12, 2015 ª2015 Elsevier Inc. 789
Table 1. Properties of Antibody Responses Produced by Various
Immunization Schemes
Scheme %surv Breadth hc hv Ctot
WT only (tmax = 80)
Ab feedback 54% 0.6% 0.45 0.39 0.3
peers only 79% 0.7% 0.49 0.43 0.5
(I) WT+v1+v2 (tmax = 240)
See 1 Ag; Ab feedback 1% 11% 0.72 0.29 0.6
peers only 1% 2% 0.52 0.22 1.0
See all Ag; Ab feedback 1% 5% 0.84 0.70 0.3
peers only 3% 3% 0.89 0.83 0.5
(II) WTjv1+v2 (tmax = 80 + 160 = 240)
See 1 Ag; Ab feedback 80% 75% 1.21 0.16 0.36
peers only 10% 35% 0.73 0.16 1.0
See both Ag; Ab feedback 31% 33% 1.07 0.37 0.3
peers only 47% 42% 1.22 0.41 0.5
(II) WTjv1jv2 (tmax = 80 3 3 = 240)
Ab feedback 43% 79% 1.38 0.22 0.33
peers only 69% 83% 1.64 0.24 0.55
%surv: percentage of seeded GCs that produce antibodies efficiently;
Breadth: defined in text; hc (hv): the average strength of interactions
with conserved (variable) residues of the epitope—large values of hc indi-
cate focusing on the conserved residues of the epitope; Ctot: antigen
concentration.
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Figure 3. Distribution of Breadth of Individual Antibodies and Their
Total Coverage for Surviving GCs in Scheme I—WT+v1+v2
(A and B) Histograms of breadth for having 11 (A) or 4 (B) non-overlapping
mutations in the two variants. Histograms are obtained as a distribution for all
the surviving GCs.
(C) Histograms of coverage for surviving GCs under the same conditions as in
(B). The coverage is defined as a sum of non-overlapping specificities. Results
are shown for the cases of ‘‘see 1 Ag’’ (filled bars) and ‘‘see all Ag’’ (unfilled
bars), with Ab feedback.
See also Figure S4.near optimal breadth (peak of red curves in Figure 2). In scheme
III, the chosen concentration is slightly higher to ensure high Ab
production.
Immunizing with a Cocktail of WT Ag and Two Variants
Fails to Elicit an Effective Response
Figure 3A shows in silico results for the distribution of the breadth
of coverage (for the Seeman panel) of Abs produced using im-
munization scheme I (cocktail of WT+v1+v2). Ag concentration
is fixed to yield the greatest breadth, but two more variables
could be important: during selection in the light zone, does a B
cell-FDC encounter involve one or all Ag variants? Is ‘‘Ab feed-
back’’ important during AM? For this immunization scheme, in
most scenarios, just a few percent of GCs survive (Table 1);
i.e., Ab titers are predicted to be low. To see why, consider first
the situation where B cells interact with only one Ag variant dur-
ing each encounter with FDCs. B cells that bind moderately
strongly to one of the three variants seed the GC, and they do
not have any strong interactions with the conserved residues
of the epitope yet. Now consider a B cell that is selected by a
particular Ag variant in an early round, then mutates, and returns
to the light zone to encounter a different variant. Without even
moderately strong contact with the conserved residues, the
probability that such a B cell is cross-reactive to the new variant
is small. Thus, apoptosis is the most likely outcome, leading to
collapse of the GC. For the rare GCs that do survive, there is evo-
lution of interactions with the conserved residues and dimunition
of interactions with variable loops during AM, and this confers
some breadth (relative to immunization with WT Ag alone, see
Table 1).790 Cell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc.If B cells interact with all Ag variants during each encounter
with FDCs, and the Ag concentration is chosen to be the one
that confers optimal breadth, the percentage of surviving GCs
and the distribution of breadth is not very different compared
to the case where only one Ag variant is encountered at a time
(Figure 3A). However, importantly, the optimal concentration is
lower when B cells can interact with all Ag variants. If the Ag con-
centrations were made the same as when B cells interact with
one Ag at a time, then most GCs would survive when all Ag
variants are simultaneously encountered (Figure S4B). This is
because, in this case, B cells that bind sufficiently strongly to
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Figure 4. Comparison of Statistics for Surviving GCs in Scheme II—WTjv1+v2 and Scheme III—WTjv1jv2
(A–F) Shown are histograms for breadth, mean interaction strength with conserved residues (hc) andwith variable residues (hv) (A–D), and for total coverage (E and
F) via a polyclonal response. Results are shown for ‘‘Ab feedback’’ (A, C, and E) and ‘‘peers only’’ (B, D, and F) scenarios. For scheme II (A and B), cases of ‘‘see 1
Ag’’ (filled bars) and ‘‘see both Ag’’ (unfilled bars) are shown. Total coverage (E and F) is presented for scheme III (WTjv1jv2) by red filled bars and for scheme II
(WTjv1+v2, see 1 Ag) by blue unfilled bars. See also Figure S5.any one Ag variant can progress through AM. As a consequence,
the generated Abs are likely to be strain specific. Thus, if Ag is
displayed homogeneously on FDCs, for immunization scheme
I, optimal conditions for inducing Abs efficiently at high titers
would not induce bnAbs. The lower Ag concentration required
for optimal breadth results in the survival of only a relatively
low fraction of GCs (Figure 3A).
We also carried out calculations where the Ag variants differ
from each other by only four non-overlapping mutations. When
all variants are simultaneously encountered in each interaction
with FDCs and Ab feedback is turned on, comparing results for
this case (Figure 3B) with that when the variants differ by 11
mutations (Figure 3A), we find that a much higher fraction
(10% versus 1%) of GCs succeed in producing Abs (Fig-
ure S4D). This is because the Ags vary less from each other,
and so the chance of a B cell being cross-reactive to variants
in early stages of AM is higher, thus increasing the probability
of it being positively selected. The breadth of the Abs pro-
duced is not large because many variable residues that are
unmutated in the Ag variants are mutated in the test panel
sequences, and strain specific Abs are likely to be produced
as all Ag variants on FDCs are simultaneously encountered.
This is why the total coverage (Figure 3C), defined as the
breadth of coverage offered by the polyclonal response from
all the Abs, is higher than the average breadth of coverage
of individual Abs (Figure 3B). Results for the case where only
one Ag variant is encountered at a time on FDCs are shown
in Figures 3B and 3C (filled bars), and for no Ab feedback
see Table 1.In our in silico studies of this immunization scheme, we did
not find any conditions that result in bnAbs with high probability
(Figure S4). This is because B cell evolution during AM is made
difficult by the potentially conflicting selective pressures
imposed by Ag variants simultaneously displayed on FDCs.
We term this phenomenon, frustrated AM. The degree to which
AM is frustrated is controlled by a complex interplay between
Ag concentration, heterogeneity of Ag display on the FDCs, the
number of mutations that separate the Ag variants, and the
extent to which Ab feedback is important.
Immunizing with WT Ag First and then a Cocktail of the
Two Variants Yields Abs with Significant Breadth in
Special Circumstances
Consider first the situation in which there is no Ab feedback and
only one Ag variant is encountered at a time on FDCs (Figure 4B
filled bars). In the first period of AM induced by the WT Ag,
moderately strong contacts with the conserved residues of the
epitope can evolve. During AM following immunization with the
cocktail, individual B cells have equal chance of encountering
either Ag variant during selection. Since the two variants have
non-overlapping mutated residues, beneficial BCR mutations
for one strain are deleterious for the other. Maturing B cell line-
ages are frustrated in satisfying these conflicting requirements
for selection in successive rounds, but less so than in scheme I
because moderately strong interactions with the conserved res-
idues have evolved during AM driven by theWT Ag prime, result-
ing in some cross-reactivity. Therefore, a greater fraction (10%)
of GCs survive compared to scheme I. Since a relatively high AgCell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc. 791
concentration is required for GC survival in this case (Figure 2A
right panel blue curve), B cells can expand readily and GCRs
terminate quickly. Short maturation times limit the average
breadth (35%, Figure 2A right, red curve), but Abs with large
breadth do evolve with low probability.
If there is Ab feedback, lower Ag concentrations still allowGCs
to mature successfully. This is because Abs produced in previ-
ous rounds of AM often have lower affinities for the encountered
Ag than the best clones produced during the current round of
mutation and selection. This confers a competitive advantage
to these best B cell clones because they are not just competing
with each other, but also with the weaker affinity Abs (‘‘Simula-
tion Methods’’ in Extended Experimental Procedures). Also,
the Abs compete effectively with unfavorable mutant cells that
may emerge and be stochastically selected only to be extin-
guished in a future round of mutation-selection. Lowering Ag
concentration diminishes the probability of selection in each
round, thus allowing AM to proceed for a longer time before all
the Ag on FDCs is internalized. This allows mutations that confer
breadth to accumulate. This balance of lowering frustration
through Ab feedback and increasing frustration by reducing Ag
concentration results in a very high survival rate for GCs and
considerable breadth in the Ab response (Figure 2A left, Fig-
ure 4A filled bars).
If multiple Ags are encountered during each interaction with
FDCs, the outcome is different (Figures 4A and 4B, unfilled
bars). Since a choice of being selected by the same variant
(rather than a randomly chosen one of the two) is always avail-
able in successive rounds of AM, the frustration is low. In most
cases, we find that B cells are selected by one of the variants
repeatedly, and so strain-specific Abs are likely to evolve (Table
1). Furthermore, access to both Ag variants allows B cells to
multiply successfully in the GC and quickly consume all the Ag
on FDCs. The duration of AM is short, so mutations that confer
breadth evolve rarely, and the average breadth is no more than
40%, regardless of the extent of Ab feedback (Table 1). For
this optimal breadth to develop, the antigen concentrations
must bemuch lower thanwhen only one Ag variant is seen during
each B cell-FDC encounter (Figure 2B versus 2A).
Our results suggest that this immunization scheme has the po-
tential to produce bnAbs (75% breadth) with high probability if
B cells encounter one Ag variant at a time on FDCs and all Abs
produced in previous rounds migrate through ongoing GCs.
Rather than the extreme situations of full Ab feedback or none
at all, there is some middle ground, and also most likely, B cells
encounter one FDC Ag variant in some rounds of selection and
all variants during others. Thus, our results suggest that, de-
pending upon circumstances, this immunization scheme pro-
duces Abs efficiently with a probability between 10%–80%,
and with average breadths ranging from 30% to 80% (Table 1).
This scheme may be analogous to what ensues in patients
who develop bnAbs upon natural infection as they are first
exposed to the infecting strain, which then diversifies. However,
the sensitivity of our results to varying conditions suggest that
it may be quite difficult to induce bnAbs consistently in diverse
patients using this immunization scheme. This is because the
conditions noted above are likely to vary between and within
individuals.792 Cell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc.Sequential Immunization with Antigen Variants Leads to
Efficient Induction of an Antibody Response with Broad
Specificity
Sequential immunization with the three Ag variants temporally
separates the mutually conflicting selective driving forces
imposed by multiple variants. Confounding effects associated
with whether one or multiple types of Ags participate in each B
cell-FDC encounter in the GC are also obviated.
Consider first the situation where there is no Ab feedback
(Figure 4D). Maturation against the WT Ag results in some
strong interactions with the conserved residues. When AM en-
sues with the first variant, two main types of lineages evolve
in the simulations (Figure S5). Both types of lineages tend to
reduce interactions with the residues that are mutated in the first
variant Ag. But, in one type of lineage, interactions with the un-
mutated variable residues in the first variant (which are mutated
in the second variant) are enhanced; in the other type of lineage,
these interactions do not change much. When the second
variant with non-overlapping mutations is introduced, the latter
lineages have a good chance of outcompeting the former ones
during AM. This is because clones that did not increase their
footprint on the variable residues that are now mutated in the
second variant can simply reduce interactions with these resi-
dues, and focus strongly only on the conserved residues of
the epitope. This is why Abs produced in scheme III exhibit a
narrow distribution of very large breadth (Figure 4D top panel)
rather than a broad distribution of Abs with moderate breadth
seen in the analogous situation using scheme II (Figure 4B top
panel, filled bars). In scheme II, lineages specific for one or
the other variant strain have a higher chance of survival. In
scheme III, Abs that focus contacts with the conserved residues
of the epitope and minimize interactions with all the variable res-
idues are more likely to emerge (Figures 4B and 4D, middle
panels).
Comparing ‘‘Ab feedback’’ (Figure 4C) and ‘‘peers only’’ sce-
narios (Figure 4D) in scheme III, we see that Ab feedback leads
to narrower distributions of Abs with large breadth, due to the
same effects of Ab feedback noted for scheme II. As shown in
Figures 4E and 4F, the distributions of total coverage for Abs pro-
duced by schemes II and III are very close when there is Ab feed-
back (Figure 4E), and the average values are both as high as
90%. If there is no Ab feedback (Figure 4F), however, scheme
III gives a similar broad coverage (89%), whereas scheme II
yields a moderate coverage (51%) even with polyclonal re-
sponses. So, scheme III is predicted to be more robust to
many varying conditions.
Experiments in Mice with a Model System Show that
Antibodies that Focus on the Conserved Residues
Emerge upon Sequential Immunization, but Not upon
Immunization with a Cocktail
Our calculations predict that, compared to the other immuniza-
tion schemes we studied, truly cross-reactive Abs that
focus contacts on the conserved residues of the epitope with
a small footprint outside are most likely to emerge robustly
upon sequential immunization with Ag variants. Immunization
with a cocktail of Ags is predicted to result in a significantly
worse outcome compared to sequential immunization. We
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Figure 5. Immunization of Mice with Variant Immunogens
(A) Schematic of an Fc-gp120 immunogen.
(B) Immunization groups and dosing schedule for mouse experiment.
(C–E) Serum titrations (day 48) of a representative mouse from each group—(C) sequential, (D) parallel, (E) core-only—on yeast displaying stripped core (black),
clone A (blue), clone B (red), or clone C (green). Each plot also includes serum from an unimmunized mouse binding to yeast displaying clone C (black dashed).
Binding data are fit to a monovalent binding isotherm of the form y = ymax dil
1=ðdil1 +K1A Þ where ‘‘dil’’ is the serum dilution and y is the binding signal in MFU.
Discussion of the fitted parameters can be found in the supplemental material.
See also Figure S6 and Table S1.note previous immunization studies that have suggested the ad-
vantages of sequential immunization of HIV Env in generating
cross-reactive Abs, in further agreement with our computational
results (Malherbe et al., 2011; Pissani et al., 2012). Here, we
tested our predictions comparing sequential immunization and
cocktails in mouse studies using precisely engineered Ag vari-
ants. It is important to note that the variant Ags we have engi-
neered are gp120 monomers of Env, not trimers. Thus, they
cannot be expected to produce bnAbs that neutralize virus par-
ticles with intact trimeric spikes. The goal of our experiments was
to precisely test whether cross-reactive Abs that focus on the
conserved residues of an epitope (CD4bs) are more likely to
develop upon sequential immunization, compared to administra-
tion of a cocktail of the same immunogens, as per our in silico
predictions.
As described in Extended Experimental Procedures, we engi-
neered variants of a minimized gp120 core protein immunogen
(the ‘‘stripped core’’) that incorporate diversification at 43 sur-
face residues outside the CD4bs, while retaining binding affinity
to the VRC01 bnAb (Table S1, Figure S6). These immunogens
are designed to present biochemically novel residues outside
the CD4bs such that only the desired CD4bs epitope is con-
served across all the immunogens.We used four engineered var-
iants (including stripped core) that fit these criteria. Our in silico
results should hold irrespective of whether three or four variants
are used.BALB/c mice were immunized intranasally with HEK293-pro-
duced immunogens fused to mouse Fc (Figure 5A) with a CpG
oligonucleotide adjuvant, following protocols described else-
where (Ye et al., 2011). Immunogens were administered every
2 weeks at a total protein dose of 50 pmol. Animals were divided
into three groups (Figure 5B). The ‘‘Sequential’’ group of four
mice was immunized sequentially with each of the four Ag vari-
ants. The ‘‘Parallel’’ group of four mice received a cocktail of
all four variants at each administration. The ‘‘core-only’’ group
of two mice was given three doses of the same stripped core
immunogen. Serum was collected every week.
Serum binding to the Ag variants was assayed by flow cytom-
etry of yeast displaying each of the four variants. Representative
curves for each of the three immunization groups are shown in
Figures 5C–5E. Sequentially immunized mice exhibit similar
binding to each of the four Ag variants, consistent with serum
that recognizes and focuses contacts with a shared epitope pre-
sented on all variants (Figure 5C). Mice immunizedwith a cocktail
of four variants show a broader spread of binding affinities,
consistent with dominant serum specificities for some variants
but not others (Figure 5D). In the mouse represented, for
example, it appears that the serum recognizes the epitope on
stripped core that is not present on clones A or C. Serum from
mice immunized only with stripped core bind strongly to stripped
core but not to the other immunogens, consistent with our immu-
nogen design objective that the four variants not share commonCell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc. 793
Figure 6. Determination of Serum Specificity for the CD4 Binding Site
(A) Fractional binding to D368R mutant versus stripped core of serum from each group after three (open markers) and four (filled markers) immunizations. The
fractional binding to D368R for antibody VRC01 at various concentrations is shown as lines: 0.21 at 93 nM (dashed line), 0.10 at 75 nM (dash-dotted line), and 0.06
at 8.2 nM (dotted line).
(B) Schematic and data from ternary complex assay in which gp120 (CD4bs shown in gray) is pre-incubated with serum then added to VRC01 yeast. The for-
mation of a ternary complex is only possible if VRC01 is able to bind to its epitope on gp120 after serum has bound. The figure shows the percentage of yeast
cells positive for mouse serum from each immunization group—sequential (solid line), parallel (dashed line), core-only (dash-dotted line)—for various time points
(mean ± SD).
(C) Schematic and data from ternary complex assay in which gp120 is pre-loaded onto VRC01 yeast then incubated with serum. The formation of a ternary
complex is only possible if serum antibodies are able to bind to their epitope(s) after VRC01 has bound. The figure shows the percentage of yeast cells positive for
mouse serum from each immunization group as above.
(D) Analysis of twomonoclonal antibodies from a sequentially immunizedmouse: fractional binding to D368R versus stripped core gp120was assayedwith 10 nM
monoclonal antibody (analogous to 6A); percentage binding in the ternary complex assay (analogous to 6C), in which gp120 is pre-bound to VRC01 yeast.surface residues outside the CD4bs (Figure 5E), like the non-
overlapping mutations in Ag variants in our calculations.
Serum specificity for the CD4bs was determined in two
ways. First, we measured the binding of serum to the stripped
core mutant D368R, which is known to disrupt the binding of
several CD4bs-directed Abs (Thali et al., 1992). Serum samples
collected after the third and fourth immunizations were incu-
bated at a 1:100 dilution with yeast displaying either stripped
core or the D368Rmutant (Figure 6A). For mice from the sequen-
tial immunization group, the fractional binding of serum to D368R
was similar to that of VRC01 at saturating concentrations. Of the
mice that were immunizedwith a cocktail of all four immunogens,
three are very sensitive to D368R after three immunizations but
appear to lose this specificity by the fourth administration.
A second assay used to determine specificity was to evaluate
the simultaneous binding of VRC01 and serum antibodies to
gp120 (Experimental Procedures). The assay was performed
first by pre-incubating the gp120 with mouse serum before intro-
ducing VRC01-displaying yeast (Figure 6B). If serum antibodies
compete with VRC01 for its binding site, the gp120-serum com-794 Cell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc.plexwill not bind to the yeast. No binding signal was observed for
any of the serum samples, suggesting that all contained some
fraction of VRC01-competitive antibodies. This result is consis-
tent with the D368R gp120 binding results discussed above.
The same assay was then performed by pre-incubating gp120
with VRC01 yeast before introducing the serum (Figure 6C) to
determine whether the serum contains any specificity other
than to the CD4bs. Note that due to plasmid loss in yeast during
culture,60%positive cells is themaximumobservable signal in
the assay. Mice immunizedwith just stripped core (53%, 56%) or
with a cocktail of four Ags (mean = 32% ± 5%) developed anti-
bodies that bind to other epitopes on gp120. However, mice
immunized sequentially did not (mean = 1.0%± 0.3%). These ex-
periments suggest that sequential immunization with Ag variants
elicited a serum response that was VRC01-competitive and
entirely focused on the conserved residues targeted by the
VRC01 Ab. Mice that were exposed to a cocktail of the variants
generated some VRC01-competitive antibodies, but also Abs
that targeted non-conserved residues on a single immunogen,
i.e., were not cross-reactive. In other words, only sequential
immunization robustly elicited a response that is focused on the
conserved residues of the desired epitope. These findings are in
harmony with our in silico results.
To establish that individual CD4bs-competitive antibodies
were generated by sequential immunization, hybridomas were
generated by splenotypic fusion from a mouse immunized using
this protocol. Two distinct gp120-bindingmonoclonal antibodies
were isolated (for sequences, see Extended Experimental Pro-
cedures). The antibodies both targeted the CD4bs epitope, as
both were disrupted by the D368R mutation (at 10 nM antibody,
fractional binding to D368R versus stripped core gp120 of 1.4%
and 15.6%) and neither was able to bind to stripped core that
had been pre-blocked with VRC01 (Figure 6D). These data
make clear that the monoclonal antibodies are indeed focused
on the CD4bs upon sequential immunization with the variant
antigens.
DISCUSSION
The induction of bnAbs against highly mutable pathogens, such
as HIV and influenza, will require immunization with Ag variants.
Rational design of immunogens and efficient immunization
protocols that elicit bnAbs requires mechanistic understanding
of a basic problem in immunobiology: viz., how AM occurs in
the presence of variant Ags. Our studies of AM in this setting
have revealed new concepts, suggested new avenues for
experimental and theoretical research, and have practical
value. An important concept that emerges is that, when multi-
ple Ag variants are used as immunogens, they can present
conflicting selection forces during AM which frustrates the evo-
lution of Abs. This phenomenon is most acutely manifested
upon immunization with a cocktail of Ag variants. In this case,
a B cell of a particular lineage that is selected in one round
by a particular Ag variant is likely, after the next round of muta-
tion, to encounter a different Ag variant on FDCs. This B cell is
unlikely to be positively selected in this encounter, thus ending
the evolution of a potentially favorable B cell lineage. The de-
gree to which AM is frustrated is determined by a complex
interplay of effects dependent on Ag concentration, how het-
erogeneously Ag variants are displayed on FDCs, the number
of mutations that separate the Ag variants, and the extent to
which previously generated Abs migrate through ongoing
GCs. Our results provide empirical evidence that these param-
eters can be tuned to achieve an optimal level of frustration.
Too much frustration prevents GC reactions from evolving
favorable mutations that confer breadth. Too low a level of frus-
tration (the extreme case being immunization with one Ag) re-
sults in the development of strain-specific antibodies. An
avenue for future theoretical research is to define a quantitative
metric of frustration that describes precisely how the degree of
frustration depends on the pertinent variables. The metric of
frustration could then be optimized to design effective immuni-
zation protocols.
Our in silico results suggest that if one primes with the WT
Ag, and then boosts with a cocktail of variants, bnAbs can
emerge but only if some special conditions hold. Such a sce-
nario may have been the driver of bnAb production in naturally
infected patients because this immunization strategy mimicsnatural infection with one strain and subsequent viral diversifi-
cation. However, our results show that deviations from these
special conditions make the evolution of bnAbs unlikely in
this setting (Table 1). This suggests that potent bnAbs evolve
during natural infection only when special conditions are met,
which happens rarely, and thus take a long time to emerge
by chance. Controlling immunization protocols precisely to
satisfy special conditions in every vaccinated individual seems
difficult. Furthermore, even if the conditions were set to
perfectly mimic a situation that resulted in the evolution of
bnAbs upon natural infection, the outcome may not be favor-
able because Darwinian evolution is inherently stochastic and
cannot be replicated exactly. So, although it is important to un-
derstand how bnAbs are produced during natural infection,
mimicking these conditions may not be an efficient way to
induce bnAbs by vaccination.
We find that when Ag variants are administered sequentially,
bnAbs can develop with relatively high probability over a wider
range of conditions than if other strategies are deployed (Table
1, and Figures 2, 3, and 4). In this case, the conflicting selection
forces due to the variant Ags are temporally separated. This can
lead to successful evolution of multiple B cell lineages that first
develop moderate interactions with the conserved residues of
the epitope and then progressively acquire mutations that evade
contacts with one set of variable residues and then another.
Evolution of a set of possible clones which have a chance at
maturing into bnAbs after AM against the first variant makes suc-
cess more likely as all of them are unlikely to go extinct during
stochasticmutation and selection upon immunizingwith the sec-
ond variant. Our in silico results predict that this immunization
strategy is superior to immunization with a cocktail of the same
set of variants, and our model experiments in mice support this
prediction.
Sequential immunization with Ag variants that share a single
epitope to induce B cells specific for the common epitope
has been tried with linear peptide epitopes derived from HIV
gp41, though the resulting Abs were non-neutralizing (Guenaga
et al., 2011; Correia et al., 2010). Past work also emphasizes the
importance of masking irrelevant epitopes, but by itself, this
strategy is insufficient for successful vaccination (Pantophlet
et al., 2003; Selvarajah et al., 2005). Our in silico and in vivo
studies suggest that precisely engineered variant intact virus
spike immunogens administered in a sequential fashion under
appropriate conditions may offer the best opportunities for in-
duction of bnAbs against HIV-1 and other highly mutable
pathogens.
EXPERIMENTAL PROCEDURES
In Silico Model
The probability of a B cell internalizing antigen is given by:
Pia =
PnA
j = 1Cje
ðEijEaÞ=kBT
1+
PnA
j = 1Cje
ðEijEaÞ=kBT : (1)
Here Cj is the concentration of Ag of type j presented on the FDCs. The sum
over the Ag index j runs through nA distinct types of Ags that B cell i could
potentially interact with simultaneously during an encounter with a FDC
bearing multiple Ag variants.Cell 160, 785–797, February 12, 2015 ª2015 Elsevier Inc. 795
The probability of a B cell to succeed in receiving T cell help is given by:
PiTh =
PnA
j = 1e
Eij=kBT
PnA
j =1e
Eij=kBT +C1tot
DPnA
j0 = 1e
Ei0 j0=kBT
E
i0 ðsiÞ
; (2)
where hPnAj0 =1eEi0 j0 =kBT ii0 ðsiÞ is the average probability of internalizing Ag of all the
other B cells present in the GC.Ctot =
PnA
j = 1Cj is the total Ag concentration, and
the dependence on this variable accounts for the observation that the number
of activated T helper cells increases with Ag dose, thus making it more likely
that B cells receive T cell help.
Binding Assay to Determine Competitiveness with VRCO1
Yeast displaying the scFv of VRC01 was incubated with soluble stripped core
gp120 and an excess of mouse antiserum. The formation of a ternary com-
plex—a sandwich of VRC01, gp120, and mouse serum—was detected as
the presence of mouse antibodies on yeast by flow cytometry (% positive
cells). The experiment was done in two ways as described in text.
See Extended Experimental Procedures for additional information.
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